|Defining the impact of injection drug use on antiretroviral|
NIH R01DA047063-01Sep 3, 2018 - Jul 30, 2023
Role: Site PI
Description: Provide ongoing input on the use of WIHS data related to HIV treatment and medication usage, study design, analysis and interpretation of study findings and our in depth knowledge of the WIHS cohort data as it is related to HIV treatment and measures of medication usage and adherence.
|EpiGenomics of Ethnic and Racial Disparities in ARV Exposure and Treatment Outcomes|
NIH/NIMHD U01 AI034989Aug 25, 2017 - Dec 31, 2018
Description: This study provides a comprehensive assessment of genes that may underlie ethnic and racial differences in ARV exposure and HIV treatment outcomes for two common regimens, and provide a robust framework to evaluate other regimens and outcomes (e.g., hypertension, type 2 diabetes) that feature ethnic and racial minority health disparities in both HIV+ and HIV- persons.
|Genetic risk factors for adverse drug responses and toxicities in women with HIV/AIDS|
NIH/NIGMS U01 AI034989Oct 1, 2016 - Jun 30, 2017
Description: The purpose of this study is to define several adverse drug reactions and toxicities (ADR/T) in 4982 women who participated in WIHS, re-sequence 80 key candidate pharmacogenes and ADR/T genes and identify common genetic and non-genetic risk factors for ADR/T in the cohort.
|Needs assessment and value proposition for translation of pharmacogenomics into clinical practice at UCSF|
UCSF Medical Center: Chancellor's Strategic Initiative Funds Jul 1, 2016 - Jun 30, 2017
Description: The UCSF Health and UCSF leaders recognize precision medicine to be a priority. Pharmacogenetic (PG), an important component of precision medicine, is not commonly practiced at UCSF. For this project the objective is to develop needs assessment and value proposition for 1 or 2 therapeutic targets around the optimal translation of PG into clinical practice at UCSF; a blue–print that can be expanded in real-time to other therapeutic targets.
|GWAS analysis of atazanavir in two biomatrices from women in HIV|
Center For AIDS Research Program Supplement P30 A1027763Nov 1, 2014 - Oct 31, 2015
Description: Using Women’s Interagency HIV Study (WIHS) research platform to discover and validate gene polymorphisms associated with atazanavir exposure estimated by a combination of intensive pharmacokinetic and sparse hair levels.
|Personalized dosing strategies for use of fludarabine in pediatric alloHCT|
UCSF Clinical Translational Science Institute (CTSI) 5KL2TR000143-10Jul 1, 2013 - Jun 30, 2016
Description: The overall goal of this proposal is to develop innovative personalized dosing strategies for use of fludarabine in pediatric alloHCT to ensure safe and efficacious drug therapy in all patients. The research proposed in this application will identify and quantify both genetic and non-genetic covariates that contribute to variability in fludarabine exposure. This research will also establish the relationship between fludarabine exposure and clinical outcomes. I am involved in the pharmacogenetics of this work including sequencing DNA samples.
|Women’s Interagency HIV Study (WIHS) V|
NIH/NIAID U01 AI034989Dec 1, 1997 - Dec 31, 2020
Description: The WIHS is the largest and longest-duration cohort study of HIV infection in women in the U.S. The San Francisco Bay Area WIHS (SF WIHS)’s aim feature special emphasis on vascular injury and pain, assess genetic contributions and examine the outcomes. We also continue our work in measuring long term exposure to antiretroviral drugs (ARVs) using hair samples and conducting Genome-Wide Association Studies. I am the pharmacogeneticist at SF WIHS.